US5458878A
(en)
*
|
1990-01-02 |
1995-10-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
|
IL116436A
(en)
|
1995-12-18 |
2006-12-31 |
Yissum Res Dev Co |
Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
|
IL118570A
(en)
*
|
1996-06-04 |
2007-06-17 |
Shai Yarkoni |
Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
|
AU716564B2
(en)
|
1996-11-06 |
2000-03-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Protease-activatable pseudomonas exotoxin A-like proproteins
|
WO1998020037A1
(en)
*
|
1996-11-08 |
1998-05-14 |
Emory University |
Method for treating certain pediatric acute leukemias
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
ATE307208T1
(de)
*
|
1997-07-11 |
2005-11-15 |
Us Gov Health & Human Serv |
Pseudomonas exotoxin-a-ähnliche chimerische immunogene
|
US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
US6645490B2
(en)
*
|
1998-03-02 |
2003-11-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
|
WO2002060935A2
(en)
*
|
2000-12-21 |
2002-08-08 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services |
A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
|
ATE468348T1
(de)
|
2001-09-26 |
2010-06-15 |
Government Of The Us Secretary |
Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
|
CA2826735C
(en)
|
2003-04-30 |
2019-06-04 |
University Of Zurich |
Methods for treating cancer using an immunotoxin
|
EP2204385A1
(de)
|
2003-11-25 |
2010-07-07 |
The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices |
Mutanten des Exotoxin A von Pseudomonas und deren Verwendungen
|
CA2583202A1
(en)
*
|
2004-10-04 |
2006-04-27 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of macromolecules
|
WO2006041906A2
(en)
*
|
2004-10-04 |
2006-04-20 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against pseudomonas infection
|
EP1885393A4
(de)
|
2005-05-18 |
2011-03-02 |
Childrens Hosp & Res Ct Oak |
Verfahren und zusammensetzungen zur immunisierung gegen chlamydien-infektionen
|
PL3006458T3
(pl)
*
|
2005-07-29 |
2018-05-30 |
The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services |
Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
|
US20070148131A1
(en)
*
|
2005-12-05 |
2007-06-28 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
EP1966246A4
(de)
*
|
2005-12-05 |
2010-01-06 |
Trinity Biosystems Inc |
Verfahren und zusammensetzungen zur nadellosen verabreichung von antikörpern
|
US20090305978A1
(en)
*
|
2006-03-16 |
2009-12-10 |
Trinity Biosystems, Inc. |
Methods for increasing the size of animals using needleless delivery constructs
|
EP2046375B1
(de)
|
2006-07-20 |
2017-04-05 |
The General Hospital Corporation |
Verfahren und zusammensetzungen zur selektiven aktivierung von protoxinen durch kombinatorisches targeting
|
US20090092660A1
(en)
*
|
2006-08-09 |
2009-04-09 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of particles
|
US8524241B2
(en)
*
|
2007-07-20 |
2013-09-03 |
The General Hospital Corporation |
Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
|
EP2197903B9
(de)
|
2007-09-04 |
2015-04-22 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Deletionen in der domäne ii von pseudomonas-exotoxin, die die nichtspezifische toxizität vermindern
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
US8936792B2
(en)
|
2009-09-11 |
2015-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with reduced immunogenicity
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
CN103068851B
(zh)
|
2010-06-16 |
2015-03-11 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
BR112013002334A2
(pt)
|
2010-07-30 |
2016-05-24 |
Medimmune Llc |
método para purificar polipeptídeos ou imunoconjugados ativos.
|
CN103249401B
(zh)
|
2010-09-15 |
2016-01-20 |
兰德尔·J·米斯尼 |
使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
EP2998320B1
(de)
|
2011-04-19 |
2018-07-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Für glypican-3 spezifische humane monoklonale antikörper und ihre verwendung
|
AU2012268013B2
(en)
|
2011-06-09 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
|
US8932586B2
(en)
*
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
CA2846608C
(en)
|
2011-09-16 |
2023-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with less immunogenic b cell epitopes
|
WO2013050725A1
(en)
|
2011-10-04 |
2013-04-11 |
King's College London |
Ige anti -hmw-maa antibody
|
CN104520331B
(zh)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
|
AU2013306076B2
(en)
|
2012-08-21 |
2018-01-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
ES2929876T3
(es)
|
2012-12-20 |
2022-12-02 |
Medimmune Ltd |
Replegamiento y purificación de moxetumomab pasudotox
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
EP3620470B1
(de)
|
2013-10-11 |
2023-07-26 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Tem-8-antikörper und deren verwendung
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
CA2937524A1
(en)
|
2014-02-05 |
2015-08-13 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
MX2016014548A
(es)
|
2014-05-07 |
2017-06-27 |
Applied Molecular Transp Llc |
Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa.
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
WO2016044383A1
(en)
|
2014-09-17 |
2016-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
EP3374396A1
(de)
|
2015-11-13 |
2018-09-19 |
The United States of America, as represented by the secretary, Department of Health and Human Services |
Anti-bcma-polypeptide und proteine
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
WO2018035046A1
(en)
|
2016-08-15 |
2018-02-22 |
President And Fellows Of Harvard College |
Treating infections using idsd from proteus mirabilis
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
US11390683B2
(en)
|
2017-05-18 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
WO2018213064A1
(en)
|
2017-05-19 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
WO2019055955A1
(en)
|
2017-09-18 |
2019-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
|
KR20210076881A
(ko)
|
2018-03-08 |
2021-06-24 |
어플라이드 몰레큘라 트랜스포트 인크. |
경구 전달용 독소-유래 전달 구조체
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
US20210292428A1
(en)
|
2018-08-08 |
2021-09-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
JP2022512976A
(ja)
|
2018-11-07 |
2022-02-07 |
アプライド モレキュラー トランスポート インコーポレイテッド |
異種ペイロードの経口送達のためのコリックス由来担体
|
AU2020206308A1
(en)
|
2019-01-08 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
EP3883971A1
(de)
|
2019-01-22 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hochaffine monoklonale antikörper gegen glypican-1 und verfahren zur verwendung
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
BR112022002962A2
(pt)
|
2019-08-16 |
2022-07-05 |
Applied Molecular Transport Inc |
Composições, formulações e produção e purificação de interleucina
|
WO2021081052A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
WO2021097289A1
(en)
|
2019-11-15 |
2021-05-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pegylated recombinant immunotoxins
|
EP4110823A1
(de)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CN116583539A
(zh)
|
2020-12-22 |
2023-08-11 |
江苏恒瑞医药股份有限公司 |
抗il-4r抗体或其抗原结合片段的复合物及医药用途
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022261017A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
WO2023114980A1
(en)
|
2021-12-17 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|